Association of the medical therapy with beta-blockers or inhibitors of renin-angiotensin system with clinical outcomes in patients with mildly reduced left ventricular ejection fraction after acute myocardial infarction

Seung-Jae Joo, MD, Song-Yi Kim, MD, Jae-Geun Lee, MD, Jong Wook Beom, MD, Joon-Hyok Choi, MD, Hyeung Keun Park, MD, Ki Yung Boo, MD, Chang-Hwan Yoon, MD, Jung-Hee Lee, MD, Jei Keon Chae, MD, Myung Ho Jeong, MD; on behalf of the KAMIR-NIH registry investigators

Abstract

In the era of the initial optimal interventional and medical therapy for acute myocardial infarction (AMI), a number of patients with mildly reduced left ventricular ejection fraction (EF) have been increasing. This observational study aimed to investigate the association between the medical therapy with oral beta-blockers or inhibitors of renin-angiotensin system (RAS) and 2-year clinical outcomes in patients with mildly reduced EF after AMI. Among patients enrolled in the Korea Acute Myocardial Infarction Registry-National Institute of Health, propensity-score matched patients who survived the initial attack and had mildly reduced EF were selected according to beta-blocker or RAS inhibitor therapy at discharge. Beta-blocker therapy at discharge was associated with lower 2-year major adverse cardiac events which was a composite of cardiac death, myocardial infarction, revascularization and re-hospitalization due to heart failure (8.7 vs 12.8/100 patient-years; hazard ratio [HR] 0.68; 95% confidence interval [CI] 0.50–0.93; P = .018), and no significant interaction between EF ≤ 45% and > 45% was observed (P interaction = 0.354). This association was mainly driven by lower myocardial infarction in patients with beta-blockers (HR 0.50; 95% CI 0.26–0.95; P = .035). Inhibitors of RAS at discharge were associated with lower re-hospitalization due to heart failure (1.8 vs 3.5/100 patient-years; HR 0.53; 95% CI 0.33–0.86; P = .010) without a significant interaction between EF ≤ 45% and > 45% (P interaction = 0.333). In patients with mildly reduced EF after AMI, the medical therapy with beta-blockers or RAS inhibitors at discharge was associated with better 2-year clinical outcomes.

Abbreviations: ACEi = angiotensin-converting enzyme inhibitors, AMI = acute myocardial infarction, ARB = angiotensin receptor blockers, BMI = body mass index, CAD = coronary artery disease, CI = confidence interval, EF = ejection fraction, eGFR = estimated glomerular filtration rate, HFmrEF = heart failure with mildly reduced ejection fraction, HFpEF = heart failure with preserved ejection fraction, HFrEF = heart failure with reduced ejection fraction, HR = hazard ratio, LV = left ventricular, MACE = major adverse cardiac events, PCI = percutaneous coronary intervention, RAS = renin-angiotensin system, STEMI = ST-elevation myocardial infarction.

Keywords: beta-adrenergic blockers, myocardial infarction, renin-angiotensin system, ventricular ejection fraction

1. Introduction

Heart failure (HF) had long been classified as HF with reduced ejection fraction (HFrEF) or HF with preserved EF (HFpEF). In most clinical trials, HFrEF was defined as EF less than 35% to 40%, and patients with EF above 40% were considered to have HFpEF. However, the 2016 European Society of Cardiology (ESC) guidelines for HF suggested an intermediate phenotype,
that is, HF with mid-range EF (EF between 40% to 49%),[10] and the 2021 ESC guidelines renamed it to HF with mildly reduced EF (HfEmREF) because retrospective analysis of clinical trials that included patients with EF in the 40% to 50% range showed some benefits from similar therapies to those with HFrEF.[11]

An optimal medical therapy as well as early coronary reperfusion therapy is recommended in patients with acute myocardial infarction (AMI) to reduce cardiovascular mortality and morbidity. The evidence of clinical benefits of beta-blockers or inhibitors of renin-angiotensin system (RAS) after AMI is based on the clinical trials which enrolled patients with left ventricular (LV) EF below 40% or clinical HF.[3–5] Their effects in AMI patients with EF > 40% have not been well documented. The clinical trials showing a long-term benefit of beta-blockers in patients with EF > 40% after AMI are still lacking, and clinical studies of RAS inhibitors in patients with stable coronary artery disease (CAD) without LV systolic dysfunction or clinical HF.[6–8] showed inconsistent results.[6–8]

In the era of early coronary reperfusion therapy, patients with mildly reduced EF after AMI have been increasing. However, the role of beta-blockers or RAS inhibitors in such patients is still unclear because they may be classified as having either preserved or reduced EF. We have already reported that beta-blocker therapy at discharge was associated with better 1-year clinical outcomes in patients with mildly reduced EF (≥40%, <50%) as well as with reduced EF (≤40%) after AMI, but not in patients with preserved EF (≥50%).[9] This finding suggested that AMI patients with mildly reduced EF be managed similarly to those with reduced EF. Nevertheless, because of different baseline characteristics of those patients with versus without beta-blocker therapy at discharge and only 1 year follow-up, this association needed to be confirmed in the propensity score-matched patients for a longer duration. Also, the role of RAS inhibitor therapy in AMI patients with mildly reduced EF was not analyzed in the previous study.

This observational study aimed to define the association between the medical therapy with beta-blockers or RAS inhibitors at discharge and 2-year clinical outcomes in patients with mildly reduced EF after AMI after propensity score matching.

2. Methods

2.1. Study population and data collection

The Korea Acute Myocardial Infarction Registry-National Institute of Health is a nation-wide, prospective, observational, and on-line registry of South Korea from 20 university hospitals. Patients who were hospitalized primarily for AMI and signed informed consents were consecutively enrolled from November 2011 to October 2015. This study was conducted according to the Declaration of Helsinki. The study protocol was approved by the ethic committee at Chonnam National University Hospital, Republic of Korea (IRB No. CNUH-2011-172) and the institutional review boards of all participating hospitals approved the study protocol. Written informed consents were obtained from participating patients or legal representative. Data were collected by the attending physician with the assistance of a trained clinical research coordinator, via a web-based case report form in the clinical data management system of the Korea NIH.[9,10] LV systolic function was evaluated with echocardiography during the initial hospitalization. Patients, who did not undergo echocardiographic study, died during index hospitalization, had incomplete clinical data or had EF ≤ 40% or ≥ 50%, were excluded.

AMI was diagnosed when there was an evidence of myocardial necrosis (a rise and/or fall in cardiac biomarker, preferably cardiac troponin), and at least one of the following: symptoms of ischemia, new or presumed new significant ST-segment-T wave changes or a new left bundle branch block, a development of pathologic Q waves in the ECG, an imaging evidence of the new loss of viable myocardium or new regional wall motion abnormality, and the identification of an intracoronary thrombus by angiography.[11] Coronary reperfusion included reperfusion by percutaneous coronary intervention (PCI), thrombolysis, or coronary artery bypass graft, myocardial infarction with non-structured coronary arteries,[12] and myocardial bridge. RAS inhibitors included angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB).

2.2. Clinical endpoints and definition

The primary endpoint was 2-year major adverse cardiac events (MACE) which was a composite of cardiac death, myocardial infarction (STEMI), revascularization and re-hospitalization due to HF. The secondary endpoints were each component of MACE, all-cause death, stroke, 2-year major adverse cardiac and cerebrovascular events which was a composite of the primary end-point and stroke, and 2-year MACE with non-cardiac death.

All deaths were considered to be associated with cardiac problems, unless a definite non-cardiac cause was established. MI included re-infarction or recurrent MI.[11] Revascularization included repeated PCI or coronary artery bypass graft on either target or non-target vessels. The staged PCI was excluded from revascularization. The clinical follow-ups were routinely performed at 6-, 12-, 24-, and 36-month by visiting the hospital or whenever any clinical events occurred. If patients did not visit the hospitals, the outcome data were assessed by telephone interview. Clinical events were not centrally adjudicated. The patient’s physician identified all events and the principal investigator of each hospital confirmed them.

2.3. Statistical analysis

Because either beta-blocker or RAS inhibitor therapy was not randomized, propensity score matching was performed as a sensitivity analysis to minimize selection or predisposition bias. The propensity score was estimated using multiple logistic regression analysis with all variables in Tables 1 and 2. Using a greedy nearest matching algorithm with 0.1 caliper width, each patient without beta-blockers or RAS inhibitors was matched to a maximum of 2 patients in beta-blocker or RAS inhibitor group. The efficacy of the propensity score model was assessed by estimating standardized differences for each covariate between groups.

Data were expressed as mean ± standard deviation or median (interquartile range) for continuous variables, and as number (percentage) for categorical variables. Data were compared using unpaired t-test for continuous variables, and chi-square test for categorical variables. Survival curves for clinical endpoints and cumulative event rates with incidence rates per 100 patient-years were generated using Kaplan–Meier estimates. Hazard ratios (HR) and their 95% confidence interval (CI) for each clinical endpoint were calculated using Cox proportional hazard analysis. In multivariate Cox regression analysis, age, sex, body mass index (BMI), hypertension, diabetes mellitus (DM), prior angina, prior MI, prior HF, current smoker, Killip class, estimated glomerular filtration rate (eGFR) by Modification of Diet in Renal Disease (MDRD) equation, LVEF, type of MI, coronary reperfusion, and medications (aspirin, P2Y12 inhibitors, beta-blockers or RAS inhibitors, and statins) at discharge were included as covariates. Subgroups that were defined post hoc according to demographic and clinical characteristics included age (<65, ≥65–<80, & ≥80 years), sex, hypertension, DM, prior MI, current smoker, Killip class ≥ 2, eGFR < 60 mL/min/1.73 m2, EF (<45% & >45%), ST-elevation myocardial infarction (STEMI), and beta-blockers or RAS inhibitors at discharge. All statistical analyses were performed with the statistical packages SPSS version 23 (IBM Corp., Armonk, NY), and R version 3.1.3 (R Foundation for Statistical Computing, Vienna, Austria). Clinical significance was defined as P < .05.
Table 1
Baseline characteristics of patients with versus without beta-blockers at discharge.

|                        | Entire cohort (N = 2904) | Propensity-score matched patients (N = 1048) |
|------------------------|--------------------------|---------------------------------------------|
|                        | With BB (N = 2508)       | Without BB (N = 396)          | SD    | P value       | With BB (N = 685)       | Without BB (N = 363)          | SD    | P value       |
| Age (yrs)              | 63.8 ± 12.4              | 67.4 ± 13.1                      | 0.268 | <.001         | 66.4 ± 11.3              | 66.8 ± 12.7                   | <.001 | .635         |
| Male                   | 1859 (74.1)              | 271 (68.4)                       | -0.105 | .020          | 480 (70.1)               | 256 (70.3)                    | .027  | .887         |
| Body mass index (kg/m²) | 23.98 ± 3.26             | 23.14 ± 3.17                     | -0.265 | <.001         | 23.50 ± 3.24             | 23.27 ± 3.17                   | -0.044 | .266         |
| Hypertension           | 1208 (48.2)              | 196 (49.5)                       | 0.028  | .627          | 325 (47.4)               | 177 (48.8)                    | .025  | .697         |
| Diabetes mellitus      | 703 (28.0)               | 107 (27.0)                       | -0.014  | .718          | 186 (27.2)               | 98 (27.0)                     | .006  | 1.000        |
| Prior angina pectoris  | 201 (8.0)                | 46 (11.6)                        | 0.103  | .020          | 65 (9.5)                 | 40 (11.0)                     | .135  | .035         |
| Prior myocardial infarction | 216 (8.6)           | 36 (9.1)                         | 0.020  | .773          | 63 (9.2)                 | 31 (8.5)                      | .014  | .820         |
| Prior heart failure    | 27 (1.1)                 | 4 (1.0)                          | -0.032  | 1.000         | 6 (0.9)                  | 3 (0.8)                       | <.001 | 1.000        |
| Prior stroke           | 170 (6.8)                | 29 (7.3)                         | 0.028  | .669          | 47 (6.9)                 | 27 (7.4)                      | .021  | .800         |
| Current smoker         | 1024 (40.8)              | 143 (36.1)                       | -0.109  | .078          | 262 (38.2)               | 135 (37.2)                    | -0.014 | .789         |
| Killip class ≥ II      | 550 (21.9)               | 110 (27.8)                       | 0.134  | .012          | 165 (24.1)               | 97 (26.7)                     | .040  | .369         |
| eGFR < 60 mL/min/1.73 m² | 450 (17.9)           | 96 (24.2)                        | 0.125  | .004          | 149 (21.8)               | 79 (21.8)                     | <.010 | 1.000        |
| Left ventricular EF (%)| 45.9 ± 2.5               | 45.5 ± 2.5                       | -0.035 | .314          | 45.7 ± 2.4               | 45.5 ± 2.5                    | .072  | .282         |
| STEmI                  | 1572 (67.2)              | 203 (51.3)                       | -0.233 | <.001         | 354 (51.7)               | 192 (52.9)                    | .041  | .745         |
| Coronary reperfusion*  | 2437 (97.2)              | 371 (93.7)                       | -0.146 | .001          | 656 (95.8)               | 349 (96.1)                    | .023  | .871         |

Medications at discharge

|                        | With RAS (N = 2316) | Without RAS (N = 588) | SD    | P value       | With RAS (N = 1003) | Without RAS (N = 556) | SD    | P value       |
|------------------------|---------------------|-----------------------|-------|---------------|---------------------|-----------------------|-------|---------------|
| Aspirin                | 2505 (99.9)         | 394 (99.5)            | -0.055 | .140          | 685 (99.7)          | 362 (99.7)            | -0.038 | .346          |
| P2Y12 inhibitor        | 2452 (99.9)         | 365 (99.2)            | -0.208 | <.001         | 655 (99.6)          | 347 (99.6)            | .015  | 1.000        |
| RAS inhibitors         | 2103 (83.9)         | 213 (53.8)            | -0.602 | <.001         | 420 (61.3)          | 207 (57.0)            | -0.019 | .186          |
| Statins                | 2378 (94.8)         | 344 (86.9)            | -0.231 | <.001         | 619 (90.4)          | 328 (90.4)            | .041  | 1.000        |

Values are mean ± standard deviation or number (%).
BB = beta-blockers, EF = ejection fraction, eGFR = estimated glomerular filtration rate by MDRD equation, RASI = inhibitors of renin-angiotensin system, SD = standardized difference, STEmI = ST elevation myocardial infarction.

*Includes reperfusion by percutaneous coronary intervention, thrombolysis, coronary artery bypass graft, myocardial infarction with non-obstructed coronary arteries (MINOCA).

3. Results

Total 13,624 consecutive patients were enrolled in the Korea Acute Myocardial Infarction Registry-National Institute of Health. After excluding 10,720 patients (1153 patients without echocardiographic data, 252 patients who died during index hospitalization, 19 patients with incomplete data, 1670 patients with EF ≤ 40%, and 7626 patients with EF ≥ 50%), 2904 patients with EF > 40%, <50% were analyzed in this study. They comprised 24% of patients who underwent echocardiographic study and survived the initial attack. Beta-blockers or RAS inhibitors were prescribed at the discretion of each index hospitalization.
patients with RAS inhibitors and 556 patients without RAS inhibitors at discharge were well balanced (Table 2).

In propensity-score matched cohorts, 2-year follow-up rates were 96% and 92% in patients with and without beta-blockers at discharge, and 95% and 94% in patients with and without RAS inhibitors at discharge, respectively. Beta-blockers were discontinued at 1- and 2-year in 9% and 18% of survived patients with beta-blockers at discharge, but were taken at 1- and 2-year in 45% and 41% of patients without them at discharge, respectively. RAS inhibitors were stopped at 1- and 2-year in 19% and 20% of survived patients with RAS inhibitors at discharge, but were taken at 1- and 2-year in 37% and 46% of patients without them at discharge, respectively.

Patients with beta-blockers at discharge showed significantly lower 2-year MACE (8.7 vs 12.8/100 patient-years) and HR was 0.68 (95% CI; 0.50–0.93; \( P = .015 \)) after full adjustment, and this association was mainly driven by lower MI (HR 0.50; 95% CI; 0.26–0.95; \( P = .035 \)) and revascularization (HR 0.62; 95% CI; 0.41–0.95; \( P = .030 \)) (Table 3 and Fig. 2). The association between beta-blocker therapy at discharge and 2-year MACE appeared to be consistent across a series of subgroups (Fig. 3). No significant interaction between EF ≤ 45% and >45% in terms of any 2-year clinical endpoints was noted (Fig. S1, Supplemental Digital Content, http://links.lww.com/MD/H476). Beta-blocker therapy at discharge was also associated with lower 2-year MACE with non-cardiac death (Table 3). Carvedilol (50%), bisoprolol (43%) and nebivolol (5%) were the major beta-blockers that prescribed at discharge (Table 4). All beta-blockers were used in lower doses than those recommended in the guidelines. They showed comparable clinical outcomes without a significant interaction (Fig. 4).

However, no significant association of RAS inhibitors at discharge with 2-year clinical endpoints except re-hospitalization due to HF was observed after full adjustment (Table 3 and Fig. 5). Patients with RAS inhibitors at discharge were associated with lower 2-year re-hospitalization due to HF (1.8 vs 3.5/100 patient-years; HR 0.53; 95% CI; 0.33–0.86; \( P = .010 \)). The association between RAS inhibitor therapy at discharge and 2-year re-hospitalization due to HF appeared to be consistent across a series of subgroups (Fig. 6), and no significant interaction between EF ≤ 45% and >45% was shown (Fig. S2, Supplemental Digital Content, http://links.lww.com/MD/H478). Perindopril (50%) and ramipril (40%) were the major ACEi’s, and candesartan (35%), losartan (24%), telmisartan (20%) and valsartan (14%) were the major ARB’s that prescribed at discharge (Table 4). All RAS inhibitors were used in lower doses than those recommended in the guidelines. They showed comparable clinical outcomes without a significant interaction (Fig. 4).

**Table 3.** Multivariate Cox-proportional hazard analysis of 2-year events after propensity-score matching.

| Events                  | With BB (N = 685) | Without BB (N = 363) | Hazard ratio* (95% CI) | \( P \) value | With RASI (N = 1003) | Without RASI (N = 556) | Hazard ratio* (95% CI) | \( P \) value |
|-------------------------|-------------------|---------------------|------------------------|------------|--------------------|-----------------------|------------------------|------------|
| MACE                    | 103 (8.7)         | 73 (12.8)           | 0.68 (0.50–0.93)       | .015       | 151 (8.9)          | 89 (8.6)              | 0.95 (0.73–1.23)       | .676 |
| Cardiac death           | 32 (2.5)          | 25 (4.0)            | 0.67 (0.38–1.16)       | .154       | 42 (2.3)           | 27 (2.7)              | 0.91 (0.55–1.49)       | .700 |
| All-cause death         | 54 (4.3)          | 38 (6.1)            | 0.60 (0.45–1.05)       | .085       | 75 (4.1)           | 45 (4.5)              | 0.96 (0.66–1.39)       | .809 |
| MI                      | 20 (1.6)          | 19 (3.1)            | 0.50 (0.26–0.95)       | .035       | 28 (1.6)           | 18 (1.8)              | 0.91 (0.50–1.67)       | .763 |
| Revascularization       | 50 (4.1)          | 38 (6.5)            | 0.62 (0.41–0.95)       | .030       | 83 (4.8)           | 39 (4.0)              | 1.22 (0.83–1.79)       | .306 |
| Heart failure†          | 29 (2.4)          | 14 (2.3)            | 1.06 (0.55–2.03)       | .868       | 33 (1.8)           | 34 (3.5)              | 0.53 (0.33–0.86)       | .010 |
| Stroke                  | 12 (1.0)          | 9 (1.4)             | 0.69 (0.29–1.66)       | .409       | 15 (0.8)           | 12 (1.2)              | 0.72 (0.33–1.55)       | .395 |
| MACCE                   | 111 (9.5)         | 78 (13.7)           | 0.70 (0.52–0.94)       | .017       | 163 (8.7)          | 98 (10.6)             | 0.92 (0.71–1.18)       | .514 |
| MACE with NCD           | 124 (10.5)        | 82 (14.3)           | 0.72 (0.54–0.96)       | .025       | 182 (10.7)         | 102 (11.0)            | 0.99 (0.78–1.27)       | .954 |

Values are number of patients with events (rate per 100 patient-years).

*Adjusted for age, sex, body mass index, hypertension, diabetes mellitus, prior angina, prior MI, prior heart failure, current smoker, Killip class, estimated glomerular filtration rate, left ventricular ejection fraction, type of myocardial infarction, coronary reperfusion, and medications (aspirin, P2Y12 inhibitors, beta-blockers or RASI, and statins) at discharge.

†Re-hospitalization due to heart failure.
4. Discussion
The main finding of this study is that the medical therapy with beta-blockers or RAS inhibitors at discharge was associated with better 2-year clinical outcomes without significant interaction between EF ≤ 45% and > 45% in patients with mildly reduced EF after AMI in the era of early coronary reperfusion and the contemporary other optimal medical therapy with antiplatelet agents and statins.

The prevalence of HFmrEF in the registries and clinical trials of HF patients was 14% to 23%.[15] Similarly to HFrEF, the most common etiology of HFmrEF was an ischemic heart disease,[14] and prior MI was an important predictor of HFmrEF.[15] Our data showed that a quarter of patients with AMI had mildly

Figure 2. Kaplan–Meier curves and adjusted hazard ratios with 95% confidence intervals for 2-year events with versus without beta-blockers at discharge in the propensity score-matched cohorts. (A) major adverse cardiac events (B) myocardial infarction (C) revascularization (D) cardiac death. BB = beta-blockers, CI = confidence interval, HR = hazard ratio, MACE = major adverse cardiac events.
reduced EF. All-cause mortality of patients with HFmrEF was intermediate between HFrEF and HFPpEF and CAD indicated a higher risk of death in HFmrEF. Therefore, patients with mildly reduced EF as well as reduced EF after AMI should be managed with an optimal medical therapy to reduce cardiovascular mortality and morbidity.

Beta-blockers' benefit in patients with HFrEF was clearly shown in previous clinical trials, and evidence-proven beta-blockers are strongly recommended in the guidelines. However, the role of beta-blockers in patients with HFPpEF or HFmrEF was not clearly proven except one meta-analysis of clinical trials which showed 41% and 52% reduction of all-cause and cardiac mortality in patients with HFmrEF in sinus rhythm. But the median EF of 40% (interquartile range 40-43%) in this meta-analysis could not provide the sufficient evidence to support the use of beta-blockers in patients with HFmrEF, especially when EF is > 45%. In HF registries, beta-blocker therapy was associated with lower all-cause mortality in patients with HFmrEF.

Likewise, no randomized clinical trials of beta-blockers in AMI patients with mildly reduced EF are available so far. In this regard, registry data may provide evidence about an optimal medical therapy.
therapy in these patients despite the inherent limitations. Previous registry data showed no association of beta-blocker therapy with reduced mortality among survivors of AMI without HF or LV systolic dysfunction (EF <30%–40%).[21,22] In our registry, beta-blocker therapy at discharge was associated with lower 2-year MACE in AMI patients with mildly reduced EF without significant interaction between EF ≤ 43% and > 45%. This association was mainly driven by lower MI, and revascularization which was partially associated with recurrent MI. AMI patients with mildly reduced EF have scarred or non-viable myocardium to some extent, and in this clinical setting, beta-blocker therapy may be effective in reducing fatal arrhythmia, myocardial ischemia, or recurrent MI.[9,22] Our data suggest that beta-blocker therapy be considered in patients with mildly reduced EF after AMI.

In MI patients with reduced EF or clinical HF, ACEi therapy was shown to reduce rates of death, MI and re-admission for HF,[4] and ARB was non-inferior to ACEi with regard to all-cause mortality and combined end point of cardiovascular death, recurrent MI or hospitalization for HF.[5] In patients with HFmrEF, a registry data showed that RAS inhibitors were associated with lower all-cause mortality,[16] and in re-analyzed data of the Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM) Programme, candesartan significantly reduced hospitalization for HF in HFmrEF, but not in HFP EF.[23]

In patients with stable CAD without LV systolic dysfunction (EF < 40%) or clinical HF, 2 large clinical trials showed ACEi’s role in reducing cardiovascular death and MI,[6,7] but other trial failed to provide further clinical benefit.[8] ARB in patients with stable CAD also did not reduce cardiac death, MI or hospitalization for HF.[24] This inconsistent result may be caused by the different clinical characteristics of enrolled patients and the rates of clinical events which were affected by the intensive risk modulating medical therapy such as anti-platelet agents, beta-blockers or statins, and optimal coronary revascularization.[8] In a meta-analysis of clinical trials in stable CAD without HF, RAS inhibitors lowered all-cause mortality, cardiovascular mortality and HF when compared with placebo, but their benefit on all-cause and cardiovascular mortality was shown only in trials with high control event rates.[25] However, the role of RAS inhibitors in AMI patients with mildly reduced EF has not been proven yet in randomized clinical trials. Only a registry data of HFmrEF showed the mortality benefit of RAS inhibitor therapy in patients with CAD.[16] In our registry, RAS inhibitor therapy at discharge was associated with lower 2-year re-hospitalization.

### Table 4

| Generic name | No. of patients | Mean dose (mg) | Median dose (mg) |
|--------------|-----------------|----------------|-----------------|
| **Beta-blockers** (N = 685) | | | |
| Carvedilol | 344 (50) | 6.0 ± 6.0 | 3.125 (3.125, 6.25) |
| Bisoprolol | 291 (43) | 2.0 ± 1.5 | 1.25 (1.25, 2.5) |
| Nebivolol | 34 (5) | 3.0 ± 1.8 | 2.5 (1.25, 5.0) |
| Metoprolol | 9 (1) | 63.9 ± 28.3 | 50 (50, 100) |
| Others | 7 (1) | | |
| **Angiotensin-converting enzyme inhibitors** (N = 659)* | | | |
| Perindopril | 329 (50) | 2.9 ± 1.3 | 2 (2, 4) |
| Ramipril | 264 (40) | 2.5 ± 1.4 | 2.5 (1.25, 2.5) |
| Captopril | 42 (6) | 24.5 ± 26.9 | 15.6 (9.4, 37.5) |
| Others | 24 (4) | | |
| **Angiotensin receptor blockers** (N = 353)* | | | |
| Candesartan | 122 (35) | 8.8 ± 3.2 | 8 (4, 8) |
| Losartan | 86 (24) | 40.6 ± 16.9 | 50 (25, 50) |
| Telmisartan | 69 (20) | 24.1 ± 19.7 | 40 (40, 40) |
| Valsartan | 50 (14) | 80.4 ± 64.3 | 40 (40, 100) |
| Others | 26 (7) | | |

Values are number (%), mean ± standard deviation, or median (interquartile range).

*A nine patients with both angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.

**Figure 4.** Adjusted hazard ratios of 2-year major adverse cardiac events in the propensity score-matched cohort according to generic names of beta-blockers at discharge. (A) adjusted hazard ratios with versus without beta-blockers (B) adjusted hazard ratios among beta-blockers. CI = confidence interval.
due to HF in AMI patients with mildly reduced EF without significant interaction between EF ≤ 45% and > 45% despite early coronary reperfusion and other guideline-directed medical therapy, and this outcome was comparable between ACEi and ARB. HFmrEF may be in the transition stage that becomes to improve to HFP EF or to progress to HFr EF, and ischemic heart disease etiology was associated with a decrease in EF. The activation of RAS after AMI causes LV dilatation and dysfunction which may induce clinical HF and this remodeling process was shown to be attenuated by RAS inhibition. Our data suggest that RAS inhibitor therapy be considered in AMI patients with mildly reduced EF to prevent HF hospitalization.

4.1. Limitations
First, this study analyzed a non-randomized, observational registry data. Beta-blockers or RAS inhibitors were prescribed at

Figure 5. Kaplan–Meier curves and adjusted hazard ratios with 95% confidence intervals for 2-year events with versus without inhibitors of renin-angiotensin system at discharge in the propensity score-matched cohorts. (A) major adverse cardiac events (B) re-hospitalization due to heart failure (C) myocardial infarction (D) cardiac death. CI = confidence interval, HR = hazard ratio, MACE = major adverse cardiac events, RASI = inhibitors of renin-angiotensin system.
the discretion of an attending physician. The information why physicians did not prescribe beta-blockers or RAS inhibitors to some patients at discharge was not available. Although we tried to adjust the potential confounding factors by multivariable and a propensity score-matched analysis, other unrecorded or residual confounders as well as selection bias could not be completely controlled. Therefore, our results should be interpreted with caution. Second, because patients’ medications were recorded only at discharge, 1-year and 2-year, we could not ascertain whether patients actually obtained them, took them as prescribed, and adhered for 2 years. In addition, a large cross-over was observed in patients without beta-blockers or RAS inhibitors at discharge, and 41% and 46% of those patients were taking beta-blockers and RAS inhibitors at 2-year, respectively. However, despite this cross-over, taking beta-blockers or RAS inhibitors from the hospital discharge was associated with improved clinical outcomes. Third, beta-blockers and RAS inhibitors at discharge were prescribed at only a quarter to half of maximal dose recommended in the guidelines, and the individual dose at the time of clinical events was not available. However, in an American registry of AMI, beta-blockers were prescribed less than a quarter of maximal dose at discharge in 60% of patients, and the lowest mortality was observed in >12.5% to 25% dose group [26]. In the Swedish Heart Failure Registry, RAS inhibitors of > 50% of target dose, compared with ≤ 50% of target dose, showed better mortality benefit in patients with HFpEF (EF ≥ 40%), but over 70% of patients were prescribed ≤ 50% of target dose [27]. The lower than maximal recommended dose may be a usual prescription pattern in “real-world” registries, and the optimal dose of beta-blockers or RAS inhibitors in patients with AMI with mildly reduced EF needs to be confirmed in a randomized clinical trial.
5. Conclusions

In patients with mildly reduced EF after AMI, the medical therapy with beta-blockers or RAS inhibitors at discharge were associated with better 2-year clinical outcomes without significant interaction between EF ≤ 45% and > 45%. These data suggest that long-term beta-blocker or RAS inhibitor therapy need to be considered in AMI patients with mildly reduced EF. This study was supported by a fund [2016-ER6304-02] by Korea Centers for Disease Control and Prevention.

Acknowledgments

We appreciate the contribution of the KAMIR-NIH investigators: Tae Hoon Ahn, MD, Department of Cardiology, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea. Ki-Bae Seung, MD, Cardiology Division, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. Chong-Jin Kim, MD, Kyunghee University Hospital at Gangdong, Seoul, Republic of Korea. Shung Chull Chae, MD, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea. Jin-Yong Hwang, MD, Department of Internal Medicine, Gyeongsang National University School of Medicine, Gyeongsang National University Hospital, Jinju, Republic of Korea. Seung-Ho Hur, MD, Keimyung University Dongsan Medical Center, Cardiovascular Medicine, Daegu, Republic of Korea. Seung-Woon Rha, MD, Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea. Kwang Soo Cha, MD, Pusan National University Hospital, Busan, Republic of Korea. Chang-Hwan Yoon, MD, Cardiovascular Center, Seoul
National University Bundang Hospital, Seongnam, Republic of Korea. Hyo-Soo Kim, MD, Cardiovascular Center, Department of Internal Medicine, Seoul, Republic of Korea. Hyeon-Cheol Gwon, MD, Heart Vascular and Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Jung-Hee Lee, MD, Division of Cardiology, Yeungnam University Medical Center, Yeungnam University College of Medicine, Daejeon, Republic of Korea. Seok Kyu Oh, MD, Division of Cardiology, Department of Internal Medicine, Wonkwang University School of Medicine, Iksan, Republic of Korea. Junghan Yoon, MD, Division of Cardiology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju Severance Christian Hospital, Wonju, Republic of Korea. Jei Keon Chae, MD, Division of Cardiology, Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, Republic of Korea. Seung-Jae Joo, MD, Department of Internal Medicine, Jeju National University College of Medicine, Jeju, Republic of Korea. In-Whan Seong, MD, Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Republic of Korea. Kyung-Kuk Hwang, MD, Department of Internal Medicine, Chungbuk National University College of Medicine, Chungbuk Regional Cardiovascular Center, Division of Cardiology, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea. Doo-II Kim, MD, Department of Internal Medicine, Inje University College of Medicine, Haeundae Puik hospital, Busan, Republic of Korea. Myung Ho Jeong, MD, Chonnam National University Hospital, Gwangju, Republic of Korea.

Author contributions

Conceptualization: Seung-Jae Joo, Hyeung Keun Park, Chang-Hwan Yoon, Jung-Hee Lee, Jei Keon Chae, Myung Ho Jeong

Data curation: Seung-Jae Joo, Song-Yi Kim, Jae-Geun Lee, Joon-Hyouk Choi, Jong Wook Beom, Ki Yung Boo

Formal analysis: Seung-Jae Joo, Joon-Hyouk Choi. Hyeung Keun Park.

Funding acquisition: Myung Ho Jeong.

Investigation: Seung-Jae Joo, Chang-Hwan Yoon, Jung-Hee Lee, Jei Keon Chae, Myung Ho Jeong

Methodology: Seung-Jae Joo, Hyeung Keun Park

Project administration: Seung-Jae Joo, Myung Ho Jeong

Resources: Seung-Jae Joo, Myung Ho Jeong

Software: Seung-Jae Joo, Joon-Hyouk Choi. Hyeung Keun Park

Supervision: Seung-Jae Joo.

Validation: Hyeung Keun Park.

Visualization: Seung-Jae Joo.

Writing – original draft: Seung-Jae Joo.

Writing – review & editing: Seung-Jae Joo, Song-Yi Kim, Jae-Geun Lee, Joon-Hyouk Choi, Jong Wook Beom, Ki Yung Boo, Hyeung Keun Park, Chang-Hwan Yoon, Jung-Hee Lee, Jei Keon Chae, Myung Ho Jeong

Correction

Affiliations b, c and d have been corrected from “b Department of Health Policy and Management, Jeju National University College of Medicine, Jeju, Republic of Korea, c Cardiovascular Center, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, d Department of Internal Medicine, Jeju National University Hospital, Jeju, Republic of Korea,” to “bDepartment of Internal Medicine, Jeju National University Hospital, Jeju, Republic of Korea, cDepartment of Health Policy and Manage-ment, Jeju National University College of Medicine, Jeju, Republic of Korea, dCardiovascular Center, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.”

References

[1] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.

[2] McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599–726.

[3] The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385–90.

[4] Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000;355:1575–81.

[5] Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893–906.

[6] Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–53.

[7] Fox KM; EURopean trial on reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782–8.

[8] Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;350:2058–68.

[9] Joo SJ, Kim SY, Choi JH, et al. Effect of beta-blocker therapy in patients with or without left ventricular systolic dysfunction after acute myocardial infarction. Eur Heart J Cardiovasc Pharmacother. 2021;7:475–82.

[10] Kim JH, Chae SC, Oh DJ, et al. MultiCenter cohort study of acute myocardial infarction in Korea- interim analysis of the Korea acute myocardial infarction registry-national institutes of health registry. Circ J. 2016;80:1427–36.

[11] Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation. 2012;126:2020–35.

[12] Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute coronary artery disease in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–77.

[13] Branca L, Sholl M, Metra M, et al. Heart failure with mid-range ejection fraction: pro and cons of the new classification of Heart Failure by European Society of Cardiology guidelines. ESC Heart Fail. 2020;7:381–99.

[14] Chiocci O, Lainscak M, Seferovic PM, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19:1574–85.

[15] Bhambhani V, Kizer JR, Lima JAC, et al. Predictors and outcomes of heart failure with mid-range ejection fraction. Eur J Heart Fail. 2018;20:651–9.

[16] Koh AS, Tay WT, Teng THK, et al. A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail. 2017;19:1624–34.

[17] Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:1810–52.

[18] Maddox TM, Jameson JR, Allen LA, et al. 2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American college of cardiology solution set oversight committee. J Am Coll Cardiol. 2021;77:772–810.

[19] Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an
individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018;39:26–35.

[20] Tsuji K, Sakata Y, Nochioka K, et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction—a report from the CHART-2 Study. Eur J Heart Fail. 2017;19:1258–69.

[21] Puymirat E, Riant E, Aissaoui N, et al. β-blockers and mortality after myocardial infarction in patients without heart failure: multicenter prospective cohort study. BMJ. 2016;354:i4801.

[22] Dondo TB, Hall M, West RM, et al. β-blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction. J Am Coll Cardiol. 2017;69:2710–20.

[23] Lund LH, Claggett B, Liu J, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail. 2018;20:1230–9.

[24] Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet. 2008;372:1174–83.

[25] Bangalore S, Fakhri R, Wandel S, et al. Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials. BMJ. 2017;356:j4.

[26] Goldberger JJ, Bonow RO, Cuffe M, et al. Effect of beta-blocker dose on survival after acute myocardial infarction. J Am Coll Cardiol. 2015;66:1431–41.

[27] Lund LH, Benson L, Dahlström U, et al. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA. 2012;308:2108–17.